Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Return on Capital Employed (2022 - 2025)

Taysha Gene Therapies' Return on Capital Employed history spans 4 years, with the latest figure at 0.34% for Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 20.0% year-over-year to 0.34%; the TTM value through Sep 2025 reached 0.34%, up 20.0%, while the annual FY2024 figure was 0.65%, 1.0% down from the prior year.
  • Return on Capital Employed for Q3 2025 was 0.34% at Taysha Gene Therapies, up from 0.45% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 2.64% in Q3 2023 and bottomed at 2.91% in Q2 2023.
  • The 4-year median for Return on Capital Employed is 0.59% (2024), against an average of 0.81%.
  • The largest annual shift saw Return on Capital Employed surged 239bps in 2023 before it crashed -318bps in 2024.
  • A 4-year view of Return on Capital Employed shows it stood at 2.88% in 2022, then surged by 83bps to 0.49% in 2023, then fell by -29bps to 0.63% in 2024, then surged by 46bps to 0.34% in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Return on Capital Employed are 0.34% (Q3 2025), 0.45% (Q2 2025), and 0.7% (Q1 2025).